PureTech Health PLC · LSE:PRTC

PureTech Health — Technical Presentation (October 2025)

11 slides from PureTech Health's technical presentation, October 2025

  1. Slide 1: LYT-200 Program Supplemental Slides

    LYT-200 Program Supplemental Slides

  2. Slide 2: Table of Contents

    Table of Contents  LYT-200 Executive Summary  LYT-200 Overview  Two-gear Approach  Catalysts & Initial Data from the Ongoing Phase 1b Trial in AML & High-risk MDS  Clinical Data 2

  3. Slide 3: First-in-class Therapeutic Targeting Galectin-9 in Oncology

    First-in-class Therapeutic Targeting Galectin-9 in Oncology First-in-class Fully human IgG4 monoclonal antibody targeting galectin-9 (Gal-9) Compelling MOA Shown direct tumor cell killing and immunomodulatory activities to date LYT-200 Biomarker Opportunity Multiple enrichment strategies using gal-9

  4. Slide 4: LYT-200 Overview

    LYT-200 Overview bad : BURETECH = o GIVING LIFE TO SCIENCE”

  5. Slide 5: Gallop Oncology: Advancing Galectin-9 Targeting mAb, LYT-200

    Gallop Oncology: Advancing Galectin-9 Targeting mAb, LYT-200 Driving immunosuppression through multiple pathways Challenge • Current therapies predominantly LYT-200 only address Gear 1 or Gear 2 Gear 1 Gear 2 Kills cancer cells Kills cancer cells Solution directly through activation of the • Novel t

  6. Slide 6: LYT-200 Clinical Data to Date in AML & High Risk MDS

    LYT-200 Clinical Data to Date in AML & High Risk MDS INITIAL DATA FROM THE PHASE 1B TRIAL HEMATOLOGIC MALIGNANCES (Data as of April 28, 2025) (Phase 1b ongoing) Favorable safety profile demonstrated to date, with no dose limiting toxicities ▶ Received Orphan Drug designation from Monotherapy arm: 30

  7. Slide 7: Clinical Data

    Clinical Data bad : BURETECH = o GIVING LIFE TO SCIENCE”

  8. Slide 8: Gallop Oncology: LYT-200 Multiple lines of preclinical data

    Gallop Oncology: LYT-200 Multiple lines of preclinical data supporting therapeutic potential SINGLE AGENT ACTIVITY IN B16F10 T CELL ACTIVATION WITH LYT-200 IN LYT-200 DRUG PROPERTIES MAKE IT MELANOMA MODEL PATIENT-DERIVED ORGANOID1 MODEL AN EXCELLENT CLINICAL CLONE: a-Gal9 lgG1 200μg+a-mPD-1 High af

  9. Slide 9: LYT-200 induces apoptosis of leukemia cells & extends survival

    LYT-200 Administration induces apoptosis of leukemia cells & extends survival of leukemia cell engrafted animals AML MODEL1 T-ALL, B-ALL & DLBCL MODEL LYT-200 cause apoptosis of AML cells and is superior to anti-TIM-3 LYT-200 cause apoptosis of B-ALL, T-ALL and DLBCL cells mAb 100 100 **** **** ****

  10. Slide 10: Phase 1b Clinical Trial in AML/MDS Ongoing

    Phase 1b Clinical Trial in AML/MDS Ongoing DOSE ESCALATION TRIAL Safety, tolerability, PK/PD, RP2D, Safety & efficacy + exploratory endpoints PATIENT POPULATION AML R/R to at least one line of prior therapy with or without allogeneic system cell transplant DOSE FINDING (4+2 DESIGN) If clinical benef

  11. Slide 11: Phase 1b Clinical Trial in Solid Tumors Completed

    Phase 1b Clinical Trial in Solid Tumors Completed SOLID TUMOR DOSE ESCALATION & DOSE CLINICAL INVESTIGATORS EXPANSION TRIAL Dose Finding (CRM) (all comers), safety, tolerability, RP2D, PK/PD, PI - Zev exploratory Wainberg Daniel Fein Up to 26 patients Gerald Falchook Siqing Fu Completed bi-monthly,

PureTech Health — Technical Presentation (October 2025) on 6ix